It’s Make or Break Time for Biogen’s Alzheimer’s Drug

(Bloomberg) -- Biogen Inc. stunned Alzheimer’s researchers in March when it said its highly awaited Alzheimer’s treatment aducanumab was unlikely to work. Seven months later, the company reversed c...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.